GCM
CYT

Ghisallo Capital Management’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Ghisallo Capital Management’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,000
Closed -$263K – 546
2021
Q3 		$263K Sell
15,000
-10,000
-40% -$187K 0.01% 425
2021
Q2 		$535K Buy
+25,000
New +$468K 0.02% 376

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Ghisallo Capital Management's CYT Position: Q4 2021 in Review

Ghisallo Capital Management sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q4 2021, closing a stake of 15,000 shares — an estimated $263K sold.

Ghisallo Capital Management first reported a position in CYT in Q2 2021 and held it in 2 quarters. The position peaked at $535K in Q2 2021. 48 funds tracked by Wall St. Rank hold CYT as of Q4 2021.

  • Ghisallo Capital Management reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Ghisallo Capital Management sold 15,000 Cyteir Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $263K.
  • Ghisallo Capital Management first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Ghisallo Capital Management's Cyteir Therapeutics, Inc. Common Stock position peaked at $535K in Q2 2021.
  • 48 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Ghisallo Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.